11:46 AM EST - Profound Medical Corp. : Has been granted Investigational Device Exemption approval from the U.S. Food and Drug Administration, for a multicenter Pivotal Clinical Trial. The objective of this trial is to evaluate the efficacy of the TULSA-PROTM System in patients with localized prostate cancer. Profound Medical Corp.
shares V.PRN are trading up $0.03 at $1.28.
